The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna's existing vaccine. It found the new vaccine was safe and was at least as ...

Moderna says it plans to offer both the mNexspike and its already approved vaccine starting in the fall. The original shot remains available for people ages 6 months and older. 5.

mNexspike becomes Moderna’s third FDA-approved product, joining Spikevax (original COVID-19 vaccine) and mResvia (RSV vaccine). Spikevax is approved/authorized for use by the FDA in individuals ...

Moderna said mNEXSPIKE was approved by the FDA for use in adults aged 65 and up, as well as some individuals aged 12 to 64. advertisement. Barron's. Moderna Stock Is Rising.

Federal documents show he disagreed with conclusions the benefits outweighed the risk of side effects, which are rare.

The Food and Drug Administration (FDA) has approved Moderna’s next-generation mRNA COVID-19 vaccine mNexspike ®.. The new vaccine is indicated for active immunization to prevent COVID-19 caused ...

FDA vaccine head Vinay Prasad restricted Moderna and Novavax COVID vaccines to high-risk groups, overriding staff advice amid ...

Health Secretary Robert F. Kennedy Jr. endorsed the expanded use of RSV vaccines for people 50 through 59 years old who are ...

The FDA has approved a new COVID-19 vaccine developed by Moderna, offering a lower-dose option aimed at older adults and people with underlying health risks. The vaccine, named mNexspike, is part ...

mNexspike becomes Moderna’s third FDA-approved product, joining Spikevax (original COVID-19 vaccine) and mResvia (RSV vaccine). Spikevax is approved/authorized for use by the FDA in individuals ...